Structure Therapeutics Inc. (GPCR) has gained over 130% in 3 months. Here is why

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have gained over 130% in the past three months, with a major surge since early ...
Insider Monkey

Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...
Nasdaq

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

Structure Therapeutics GPCR, a clinical-stage company, is expected to report second-quarter 2024 results soon. Structure Therapeutics’ lead product candidate is GSBR-1290, a highly selective oral ...
Business Insider

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Nasdaq

Structure Therapeutics initiated with a Buy at Stifel

Stifel initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $50 price target Structure aims to expand the reach of metabolic treatments across the large, heterogeneous obesity ...
Insider Monkey

Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts?

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...